BioSpace News Archive

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-106 for the treatment of Angelman syndrome.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a general business update.

Jadeite Medicines Inc. entered into an exclusive licensing agreement with Albireo Pharma, Inc. for the development and commercialization of odevixibat in Japan for progressive familial intrahepatic cholestasis, Alagille syndrome and biliary atresia.

Sen-Jam Pharmaceutical has identified novel combinations of proven, safe drug molecules to address COVID-induced inflammation

Akadeum Life Sciences, Inc., announced the closing of an oversubscribed $17.5 million Series B financing led by Arboretum Ventures.

Mayo Clinic announced an agreement on Tuesday, Oct. 12 that will allow it to offer clinical-grade comprehensive cancer genomic sequencing to cancer patients who choose to participate.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced two research collaborations with Massachusetts General Hospital (MGH), the largest hospital-based research program in the U.S. that delivers care grounded in leading-edge research, advanced treatment offerings and the latest clinical trials.

Berkery Noyes Securities is pleased to announce it has been retained by Eliaz Therapeutics (“ETI”), developer of a groundbreaking, patent-protected therapeutic apheresis device (XGAL3®) that effectively removes Galectin-3 (GAL-3) from the blood plasma, as its financial advisor to assist the company in raising capital for the purposes of continued development and clinical trial advancement.

The conference will be held virtually on October 13-14, 2021. Luke Hayes, Chief Financial Officer, will provide a live overview of Tryp’s activities and elaborate on how the Company is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the commercial launch of AlloSure Lung to coincide with the CHEST 2021 Meeting starting on October 16.